- Details
- Alicia Morgans engages Oliver Sartor in a discussion on implementing PSMA theranostics and the challenges related to imaging and treating patients with Lutetium. With the approval of Lutetium stirring the field, Dr. Sartor clarifies the foundational role of imaging, particularly with the PSMA 11 Ga-68 scan, in the treatment process. He highlights the need for an authorized user and a particular li...
|
- Details
- Alicia Morgans speaks with Michael Morris about the practical considerations for the clinical utilization of Lutetium-PSMA-617 outside of a clinical trial setting. Dr. Morris emphasizes the necessity of a well-coordinated, multidisciplinary approach to patient care, ensuring each team member understands their role in the process, from handling patient safety checks to maintaining communication wit...
|
- Details
- Paul Nguyen discusses a groundbreaking paper on health equity in prostate cancer with its authors, Bhav Jain and Christopher Dee. The paper focuses on racial disparities in treatment delays among younger men with prostate cancer. Utilizing the National Cancer Database, the study reveals that young Black men experience treatment delays more frequently than their older Black or White counterparts. T...
|
- Details
- Alicia Morgans converses with Scott Tagawa about patient-reported outcomes in men undergoing PSMA targeted radiopharmaceutical treatments for prostate cancer. The discussion centers on a Department of Defense-funded study that aims to develop a new patient-reported outcome tool specifically for this patient population. Dr. Tagawa elaborates on the instruments commonly used in clinical trials, such...
|
- Details
- Alicia Morgans and Phuoc Tran explore the intricacies of treating oligometastatic prostate cancer, focusing on high-risk patients identified through advanced PSMA-based imaging. Originating from ASCO 2021 case-based discussions, they emphasize the need to reconcile modern imaging data with historical treatment evidence. Dr. Tran notes that these high-risk patients may benefit from hormone therapy...
|
- Details
- In a comprehensive discussion led by Charles Ryan, James Gulley delves into the role of genomic testing and immunotherapy in treating prostate cancer. Dr. Gulley emphasizes the importance of personalized treatment, highlighting studies that identify specific genomic markers like homologous recombination deficiency and mismatch repair deficiency. These markers can guide the use of targeted therapie...
|
- Details
- In a discussion between Charles Ryan and Nima Sharifi, the focus is on the complexities of targeting the androgen-androgen receptor interaction in prostate cancer. Dr. Sharifi categorizes tumors into three types: androgen-dependent, castration-resistant via androgen agnostic pathways, and those resistant through androgen and androgen receptor agnostic mechanisms. He introduces the gene HSD3B1, whi...
|
- Details
- Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows high-risk adverse pathologic features (adjuvant radiotherapy) or if they experience biochemical recurrence (salvage radiotherapy). Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/A...
|
- Details
- Samir Taneja joins a panel of urologists to debate the use of ultrasound when compared to magnetic resonance imaging (MRI) as the best diagnostic and guidance imaging option for prostate cancer patients. Prostate ultrasound, specifically, micro-ultrasound, has a high sensitivity for predicting clinically significant cancer however its diagnostic accuracy is dependent on the urologist performing th...
|
- Details
- In this Journal Club, Zachary Klaassen discusses a study on surgeon age with Raj Satkunasivam and Chris Wallis each an author on the paper titled, "Relationship Between Surgeon Age and Postoperative Outcomes, A Population-Based Cohort Study,” published in the Canadian Medical Association Journal. The surgical workforce, especially for urologists, is aging. This study aimed to determine whether pos...
|
